Ono Pharmaceutical (OTCMKTS:OPHLF) Sets New 52-Week High – Here’s What Happened

Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $14.8332 and last traded at $14.8332, with a volume of 100 shares traded. The stock had previously closed at $12.8696.

Ono Pharmaceutical Price Performance

The business has a 50-day moving average of $13.05 and a 200 day moving average of $11.91. The company has a current ratio of 2.99, a quick ratio of 2.50 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $6.97 billion, a P/E ratio of 21.19 and a beta of 0.24.

Ono Pharmaceutical (OTCMKTS:OPHLF) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. Ono Pharmaceutical had a return on equity of 6.13% and a net margin of 9.75%.The business had revenue of $876.10 million for the quarter, compared to analyst estimates of $790.87 million.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.